How is Insulet (PODD) doing?

Insulet is a company in the medical, devices industry, based in Acton, MA, worth $9.4B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Weak

Insulet shares are down 57% over the past year, 63 points behind the S&P 500. Its type is Coiled Spring. Among large US stocks and funds it ranks in the 1st percentile on market beat, the 57th on staying power and the 92nd on business growth. It appears on 8 of our dashboards.

$135.28−57% in a yearWorth $9.4B

Compare with DXCM · MDT · ABT · RMD · WST

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

PODD against the S&P 500, past year

$100 a year ago. Insulet −57%, the S&P 500 +16%.

PODDS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Coiled Spring

LaggingSteadyGrowingBought

Behind the market but holding its rank, with a growing business and buyers stepping in.

NovDecJanFebMarAprMayJunJulAugSepNow

Coiled Spring since Feb; Churning Winner before that.

Also Coiled Spring (60 in all): INSP · IDXX · ALNY · BSX · AFRM · RRC

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

PODD, past year−57%86 of 86 in the group

Rest of the group+22%equal-weighted

S&P 500+16%past year

Insulet is −57% over the past year, against +22% for the rest of the group and +16% for the S&P 500. It ranks 86th of 86 in Health care.

PODDRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupBSX Boston Scientific−56%RARE Ultragenyx−50%ALNY Alnylam Pharmaceuticals−48%

Its closest rivalsDXCM Dexcom+24%MDT Medtronic−10%ABT Abbott Laboratories−26%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

Calmer than usual Insulet typically moves 3.1% in a day, calmer than usual for it, and it swings more than 74% of large US stocks.

Typical day3.1%about $4.17 a share

Its usual3.9%calmer than usual, 0.8× its year’s average

Against the S&P 5003.5×the index’s typical day is 1.1%

Unusual day±6.2%twice its typical day

Deepest fall, past year−62%now 61% below its high

In the S&P’s down weeks55%of the index’s fall, three years; beta 0.6

Typical daily move (ATR)Its year’s average 3.93%

PODD on our dashboards

Every question where Insulet appears, in the order of the home page, with its reading and place in that table. Select a question to open it with PODD highlighted. Select a column to sort.

Question	Reading	Place	Details
How far are stocks from their highs? Market health	92Growing	7 of 60	Below high −61% · Days since high 222 · 1Y change −57%
What are this year’s biggest winners and losers? What’s leading	1Bottom	38 of 60	This year −52% · vs S&P −67 pts · Past month 0%
Is the market rewarding earnings beats? Earnings	–Beat	24 of 60	Surprise +13% · Move vs S&P −16.1% · Reported 2026-08-05
Which companies are growing fastest? Business quality	92Fast	43 of 60	Revenue, 1Y +29% · Change +3 pts · Earnings, 1Y +59%
Who is outgrowing its rivals? Business quality	93Outgrowing	33 of 60	Revenue, 1Y +29% · Rivals +10% · Lead +20 pts
Which businesses are getting better? Business quality	92Improving	41 of 60	Revenue growth +32% · Cash-flow growth +48% · Operating margin 17%
Who is spending big on expansion? Business quality	93Ramping	25 of 60	Capex, 1Y +80% · A year $212.9M · % of revenue 7%
Which stocks are cheap against their own history? Value	100Cheap	12 of 60	P/E now 25.3x · 10-yr median 1125.6x · Earnings, 1Y +63%

Go deeper on Stox

PODD’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open PODD on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see PODD’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›DXCM · Dexcom ›MDT · Medtronic ›ABT · Abbott Laboratories ›